Juvelook vs exosomes: two very different things
Juvelook is a defined medical device: PDLLA particles in hyaluronic acid, licensed by Korea’s MFDS as a Class 4 product. “Exosome” treatments are not one product but a family of preparations of cell-derived vesicles; in Korea, exosome products for the skin are sold as cosmetics, and the US FDA says no exosome product has its approval. The two are not interchangeable.
Written by the Seoul Skin Boosters editorial team and medically reviewed by a Korean Board-Certified Dermatologist (AAD International Fellow · ASLMS member). Last reviewed: .
Why are Juvelook and exosomes compared?
Both are marketed in Seoul with the same words: regeneration, collagen, glow. That shared vocabulary hides a basic difference. One is a specific product with a stated composition and a licence; the other is a category name covering many products made in different ways.
What is Juvelook?
Juvelook, made by Vaim in Korea, contains porous poly-D,L-lactic acid (PDLLA) particles in non-cross-linked hyaluronic acid. The standard vial holds 42.5 mg of PDLLA and 7.5 mg of hyaluronic acid; Juvelook Volume holds 170 mg and 30 mg (manufacturer’s site, checked 18 October 2026). In the MFDS database, both sit under permit 제허17-972호, a Class 4 licence to “temporarily improve facial wrinkles in adults”.
The evidence is modest but specific. In a prospective study of 15 women treated under the eyes with three sessions, investigator-rated improvement scores moved from 2.93 to 2.13 (lower is better) and no adverse events were reported [1]. The main serious risk is the one shared by particle injectables: accidental injection into a blood vessel. One case of visual loss after a PDLLA-HA product has been reported [2], and experts have published a management consensus for the Juvelook Volume strength [3]. At Delight Dermatology Clinic in Seoul, a Juvelook skin booster session is listed at KRW 150,000–300,000 for 3 cc (prices checked 2026-10-18; confirm at consultation). More detail is on the Juvelook page.
What are exosomes?
Exosomes are tiny vesicles that cells release to carry proteins, fats and genetic material to other cells. In aesthetic products the word is used loosely: a 2026 review notes that many preparations sold as exosomes are better described as small extracellular vesicles, because their origin inside the cell is not always shown [4].
Products differ in their biological source, how vesicles are isolated, how many there are and what they carry. Another 2026 review lists low yields, variable cargo and the lack of agreed quality and potency measures among the main limitations, and notes that the benefits seen in early human studies come mainly from exosomes used as add-ons to microneedling, lasers or dressings [5].
What is the regulatory status of exosome products?
In the United States, the FDA’s consumer alert on regenerative medicine products (content current as of 9 April 2024) states that exosome products intended to treat diseases or conditions require FDA approval, and that there are currently none with that approval. Its December 2019 safety notification followed reports of serious adverse events in patients in Nebraska who received unapproved products marketed as containing exosomes (both pages checked 18 October 2026).
In Korea, exosome products for the skin are sold as cosmetics. The Cosmetics Act (Article 2, version in force from 8 October 2026) defines a cosmetic as a product applied, rubbed or sprayed onto the body with only a mild effect, a definition that does not extend to injection. At a 2022 parliamentary audit the head of MFDS said exosomes were sold as cosmetics and could not be used for injection, as reported by Dailypharm. In August 2024 the news agency Newsis reported that the Ministry of Health and Welfare had told doctors that injecting such products in clinics conflicts with medical law.
What does the evidence show for each?
For Juvelook, the published studies are small and mostly uncontrolled, but each one describes a defined product and dose. For exosomes, the literature is broad but heterogeneous: products, doses and outcome measures differ from study to study, high-quality clinical trials are scarce, and reports of adverse reactions linked to unapproved exosome-labelled products have prompted calls for stronger oversight [4]. A result from one exosome product says little about another.
What would stronger exosome evidence look like?
Reviewers agree on what is missing. The 2026 dermatology review names consistent manufacturing, agreed characterisation panels, meaningful potency tests, data on where vesicles travel in the body, and comparative trials that follow outcomes and safety over years rather than weeks [5]. Until those exist, two exosome products with the same label can differ as much as two unrelated creams.
Juvelook’s gaps are different but real: it has a fixed composition and a licence, yet its studies are small and short. It lacks the kind of large randomised trial that sits behind SKINVIVE or Sculptra, and exosome studies are harder still to compare.
Juvelook vs exosomes at a glance
| Juvelook | Exosome products | |
|---|---|---|
| What it is | One product: PDLLA particles in hyaluronic acid | A category of vesicle preparations from various sources |
| Korean status | MFDS Class 4 medical device licence | Sold as cosmetics for application to the skin |
| US status | No FDA record | FDA states none has its approval |
| How it is used | Injected into or under the skin | Applied to the skin; early studies paired it with microneedling or lasers |
| How it is meant to work | Gradual collagen stimulation | Cell signalling; mechanism and dose vary by product |
| Evidence | Small studies of a defined product | Heterogeneous studies of different products |
Which should you consider?
If you want an injectable for skin quality, compare licensed products on their own evidence: PDLLA such as Juvelook for gradual collagen stimulation, polynucleotides such as Rejuran, or a hyaluronic acid booster such as SKINVIVE, whose main trial documented improvement at one month [6]. They have different mechanisms and aims, and we found no head-to-head comparison with exosome products. If a clinic elsewhere offers exosomes, ask four things: the product name, its source cells, its licence in that country, and whether it will be injected or applied to the skin.
Is Juvelook an exosome treatment?
No. Juvelook contains PDLLA particles and hyaluronic acid, and no exosomes.
Are exosome injections approved in Korea?
Exosome products for the skin are sold in Korea as cosmetics, which the Cosmetics Act defines by application to the body, not injection. The MFDS head told a 2022 parliamentary audit that they could not be used for injection, according to press reports.
Is an exosome treatment safer than Juvelook because it is applied to the skin?
We found no head-to-head safety comparison. Applying a product to intact skin avoids the risk of injection into a blood vessel, but use after microneedling or laser treatment needs evidence for that product and protocol.
Can exosomes be combined with Juvelook?
Some clinics pair an exosome cosmetic with other treatments. Ask what study supports the specific product and combination, since results from one exosome product do not carry over to another.
References
Bibliographic records retrieved from PubMed (U.S. National Library of Medicine).
Young SM, Lau EKH. Hybrid Biostimulator and Hyaluronic Acid Injectable for Tear Trough Rejuvenation. Aesthetic Plast Surg. 2026;50(13):5337-5343.
PubMed: 42098500Young SM, Goh ASC, Jeyabal P, Ooi ASH. Visual Loss in Biostimulator Injectables: A Review of Incidence, Risk Factors, Etiology and Management Proposal. Aesthetic Plast Surg. 2026;50(5):1994-2005.
PubMed: 41263987Lau KHE, Young S, Goh A, et al. Consensus Opinion on Safe Injection Technique and Management of PDLLA-HA200-Induced Visual Impairment. J Craniofac Surg. 2026;37(5):1103-1109.
PubMed: 41359890Contreras C, Ariza-Donado A. Extracellular Vesicles in Regenerative and Cosmetic Medicine: Safety, Clinical Effectiveness, Therapeutic Applications, and Regulatory Challenges. Int J Mol Sci. 2026;27(12).
PubMed: 42353255Pham GM. Exosome-Based Therapeutics in Dermatology and Beyond: A Narrative Review. Biomedicines. 2026;14(2).
PubMed: 41751237Alexiades M, Palm MD, Kaufman-Janette J, et al. A Randomized, Multicenter, Evaluator-blind Study to Evaluate the Safety and Effectiveness of VYC-12L Treatment for Skin Quality Improvements. Dermatol Surg. 2023;49(7):682-688.
PubMed: 37163665